Risultati della ricerca - Lauren Pinter‐Brown
- Mostra 1 - 20 risultati su 21
- Vai alla pagina seguente
-
1
-
2
-
3
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma di Madeleine Duvic, Lauren Pinter‐Brown, Francine M. Foss, Lubomir Sokol, Jeffrey L. Jorgensen, Pramoda Challagundla, Karen M. Dwyer, Xiaoping Zhang, Michael R. Kurman, Rocco Ballerini, Li Liu, Youn H. Kim
Pubblicazione 2015Artigo -
4
A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma di Andres Forero‐Torres, John P. Leonard, Anas Younes, Joseph D. Rosenblatt, Pauline Brice, Nancy L. Bartlett, André Bosly, Lauren Pinter‐Brown, Dana A. Kennedy, Eric L. Sievers, Ajay K. Gopal
Pubblicazione 2009Artigo -
5
Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma tre... di Robert Stuver, Niloufer Khan, Marc Schwartz, Mark Acosta, Massimo Federico, Christian Gisselbrecht, Steven M. Horwitz, Frederik Lansigan, Lauren Pinter‐Brown, Barbara Pro, Andrei R. Shustov, Francine M. Foss, Salvia Jain
Pubblicazione 2019Artigo -
6
Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> di Eleni Anastasiadou, Anita G. Seto, Xuan Beatty, Melanie Hermreck, Maud-Emmanuelle Gilles, Dina Stroopinsky, Lauren Pinter‐Brown, Linda Pestano, Cinzia Marchese, David Avigan, Pankaj Trivedi, Diana M. Escolar, Aimee L. Jackson, Frank J. Slack
Pubblicazione 2020Artigo -
7
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma di Auris Huen, Bradley M. Haverkos, Jasmine M. Zain, Radhakrishnan Ramchandren, Mary Jo Lechowicz, Sumana Devata, Neil J. Korman, Lauren Pinter‐Brown, Yasuhiro Oki, Prajak J. Barde, Ajit Nair, Kasi V. Routhu, Srikant Viswanadha, Swaroop Vakkalanka, Swaminathan P. Iyer
Pubblicazione 2020Artigo -
8
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses di Bertrand Coiffier, Barbara Pro, H. Miles Prince, Francine M. Foss, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Franck Morschhauser, Martin Wilhelm, Lauren Pinter‐Brown, Swaminathan P. Iyer, Andrei R. Shustov, Tina Nielsen, Jean Nichols, Julie Wolfson, Barbara Balser, Sarah McCue Horwitz
Pubblicazione 2014Artigo -
9
A phase <scp>II</scp> study of cyclophosphamide, etoposide, vincristine and prednisone (<scp>CEOP</scp>) Alternating with Pralatrexate (P) as front line therapy for patients with p... di Ranjana H. Advani, Stephen M. Ansell, Mary Jo Lechowicz, Anne Beaven, Fausto R. Loberiza, Kenneth R. Carson, Andrew M. Evens, Francine M. Foss, Steven M. Horwitz, Barbara Pro, Lauren Pinter‐Brown, Sonali M. Smith, Andrei R. Shustov, Kerry J. Savage, Julie M. Vose
Pubblicazione 2015Artigo -
10
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study di Myron S. Czuczman, Luis Fayad, Vincent Delwail, Guillaume Cartron, Eric D. Jacobsen, Kazimierz Kuliczkowski, Brian K. Link, Lauren Pinter‐Brown, John Radford, Andrzej Hellmann, Eve Gallop‐Evans, Christine DiRienzo, Nancy Goldstein, Ira Gupta, Roxanne C. Jewell, Thomas S. Lin, Steen Lisby, Martin Schultz, Charlotte Russell, Anton Hagenbeek
Pubblicazione 2012Artigo -
11
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study di Owen A. O’Connor, Barbara Pro, Lauren Pinter‐Brown, Nancy L. Bartlett, Leslie Popplewell, Bertrand Coiffier, Mary Jo Lechowicz, Kerry J. Savage, Andrei R. Shustov, Christian Gisselbrecht, Eric D. Jacobsen, Pier Luigi Zinzani, Richard R. Furman, André Goy, Corinne Haïoun, Michael Crump, Jasmine Zain, Eric D. Hsi, Adam P. Boyd, Steven M. Horwitz
Pubblicazione 2011Artigo -
12
Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project Network di Massimo Federico, Monica Bellei, Luigi Marcheselli, Marc Schwartz, Martina Manni, Vittoria Tarantino, Stefano Pileri, Young Hyeh Ko, María Elena Cabrera, Steven M. Horwitz, Won S. Kim, Andrei R. Shustov, Francine M. Foss, Arnon Nagler, Kenneth R. Carson, Lauren Pinter‐Brown, Silvia Montoto, Michele Spina, Tatyana Feldman, Mary Jo Lechowicz, Sonali M. Smith, Frederick Lansigan, Raúl Gabús, Julie M. Vose, Ranjana H. Advani
Pubblicazione 2018Artigo -
13
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry di Frederick Lansigan, Steven M. Horwitz, Lauren Pinter‐Brown, Steven T. Rosen, Barbara Pro, Eric D. Hsi, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A. Bellm, Mark Acosta, Andrei R. Shustov, Ranjana H. Advani, Tatyana Feldman, Mary Jo Lechowicz, Sonali M. Smith, Anil Tulpule, Michael Craig, John P. Greer, Brad S. Kahl, Joseph W. Leach, Neil Morganstein, Carla Casulo, Steven Park, Francine M. Foss
Pubblicazione 2019Artigo -
14
A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States di Kenneth R. Carson, Steven M. Horwitz, Lauren Pinter‐Brown, Steven T. Rosen, Barbara Pro, Eric D. Hsi, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A. Bellm, Mark Acosta, Andrei R. Shustov, Ranjana H. Advani, Tatyana Feldman, Mary Jo Lechowicz, Sonali M. Smith, Frederick Lansigan, Anil Tulpule, Michael Craig, John P. Greer, Brad S. Kahl, Joseph W. Leach, Neil Morganstein, Carla Casulo, Steven I. Park, Francine M. Foss
Pubblicazione 2016Artigo -
15
The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter co... di Steven I. Park, Steven M. Horwitz, Francine M. Foss, Lauren Pinter‐Brown, Kenneth R. Carson, Steven T. Rosen, Barbara Pro, Eric D. Hsi, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A. Bellm, Mark Acosta, Ranjana H. Advani, Tatyana Feldman, Mary Jo Lechowicz, Sonali M. Smith, Frederick Lansigan, Anil Tulpule, Michael Craig, John P. Greer, Brad S. Kahl, Joseph W. Leach, Neil Morganstein, Carla Casulo, Andrei R. Shustov
Pubblicazione 2019Artigo -
16
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study di Reinhard Dummer, H. Miles Prince, Sean Whittaker, Sarah McCue Horwitz, Youn H. Kim, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Herbert Eradat, Lauren Pinter‐Brown, José Antônio Sanches, Pablo L. Ortiz‐Romero, Oleg E. Akilov, Larisa J. Geskin, Auris Huen, Jan Walewski, Yinghui Wang, Julie Lisano, Akshara Richhariya, Joseph Feliciano, Yanyan Zhu, Veronica Bunn, Meredith Little, Erin Zagadailov, Mehul Dalal, Madeleine Duvic
Pubblicazione 2020Artigo -
17
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data di Sarah McCue Horwitz, Julia Scarisbrick, Reinhard Dummer, Sean Whittaker, Madeleine Duvic, Youn H. Kim, Pietro Quaglino, Pier Luigi Zinzani, Oliver Bechter, Herbert Eradat, Lauren Pinter‐Brown, Oleg E. Akilov, Larisa J. Geskin, José Antônio Sanches, Pablo L. Ortiz‐Romero, Michael Weichenthal, David C. Fisher, Jan Walewski, Judith Trotman, Kerry Taylor, Stéphane Dalle, Rudolf Stadler, Julie Lisano, Veronica Bunn, Meredith Little, H. Miles Prince
Pubblicazione 2021Artigo -
18
Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC‐CLTG/ISCL survey di Pietro Quaglino, Julia Scarisbrick, Gabriele Roccuzzo, Alejandra Abeldaño, Maxime Battistella, Chris McCormack, Richard Cowan, Antonio Cozzio, Jade Cury‐Martins, Paula Enz, Larisa J. Geskin, Emmanuella Guenova, Youn H. Kim, Robert Knobler, Ivan V. Litvinov, Tomomitsu Miyagaki, Montserrat Molgó, Jan P. Nicolay, Evangelina Papadavid, Lauren Pinter‐Brown, Ramón Pujol Vallverdú, Christiane Querfeld, Pablo L. Ortiz‐Romero, Rudolf Stadler, Maarten H. Vermeer, M. Bagot, Emmilia Hodak
Pubblicazione 2023Artigo -
19
Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis di Youn H. Kim, H. Miles Prince, Sean Whittaker, Sarah McCue Horwitz, Madeleine Duvic, Oliver Bechter, José Antônio Sanches, Rudolf Stadler, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Herbert Eradat, Lauren Pinter‐Brown, Pablo L. Ortiz‐Romero, Oleg E. Akilov, Judith Trotman, Kerry Taylor, Michael Weichenthal, Jan Walewski, David C. Fisher, Marise McNeeley, Alejandro A. Gru, Lisa Brown, Maria Corinna Palanca-Wessels, Julie Lisano, Matthew Onsum, Veronica Bunn, Meredith Little, William L. Trepicchio, Reinhard Dummer
Pubblicazione 2021Artigo -
20
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cu... di Elise A. Olsen, Sean Whittaker, Youn H. Kim, Madeleine Duvic, H. Miles Prince, Stuart R. Lessin, Gary S. Wood, Rein Willemze, Marie‐France Demierre, Nicola Pimpinelli, Maria Grazia Bernengo, Pablo L. Ortiz‐Romero, M. Bagot, Teresa Estrach, Joan Guitart, Robert Knobler, José Antônio Sanches, Keiji Iwatsuki, Makoto Sugaya, Reinhard Dummer, Mark R. Pittelkow, Richard T. Hoppe, Sareeta Parker, Larisa J. Geskin, Lauren Pinter‐Brown, Michael Girardi, Günter Burg, Annamari Ranki, Maarten H. Vermeer, Sarah McCue Horwitz, Peter Heald, Steven T. Rosen, Lorenzo Cerroni, Brigette Dréno, Eric C. Vonderheid
Pubblicazione 2011Artigo
Strumenti per la ricerca:
Soggetti correlati
Medicine
Internal medicine
Lymphoma
Oncology
Chemotherapy
Immunology
Refractory (planetary science)
Surgery
Astrobiology
Gastroenterology
Mycosis fungoides
Physics
Adverse effect
Immune system
Clinical trial
Peripheral T-cell lymphoma
T cell
Anaplastic large-cell lymphoma
Clinical endpoint
Confidence interval
Dermatology
Phases of clinical research
Brentuximab vedotin
CD30
Cutaneous T-cell lymphoma
Hazard ratio
Proportional hazards model
Prospective cohort study
Rash
Antibody